Elizabeth H. Stover, Niya Xiong, Andrea P. Myers, Nabihah Tayob, Victoria Engvold, Madeline Polak, . . . Panagiotis A. Konstantinopoulos. (2022). A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Elsevier.
Chicago Style (17th ed.) CitationElizabeth H. Stover, et al. A Phase II Study of MK-2206, an AKT Inhibitor, in Uterine Serous Carcinoma. Elsevier, 2022.
MLA (9th ed.) CitationElizabeth H. Stover, et al. A Phase II Study of MK-2206, an AKT Inhibitor, in Uterine Serous Carcinoma. Elsevier, 2022.
Warning: These citations may not always be 100% accurate.